Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors

Abstract

The present application is directed to a method of treating diseases of the central nervous system (CNS) comprising administering to a individual in need of treatment a therapeutically effective amount of an inhibitor of histone deacetylase. In particular embodiments, the CNS disease is a neurodegenerative disease. In further embodiments, the neurogenerative disease is an inherited neurodegenerative disease, such as those inherited neurodegenerative diseases which are polyglutamine expansion diseases. The individual can be a mammal such as a primate or human.

What is claimed is:  
     
         1 . A method of inhibiting histone deacetylase in the brain of a mammal comprising administering to the mammal a histone deacetylase inhibiting amount of a histone deacetylase inhibitor compound.  
     
     
         2 . The method of  claim 1 , wherein the histone deacetylase inhibitor compound is selected from:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.  
     
     
         3 . The method of  claim 2 , wherein the histone deacetylase inhibitor compound is selected from:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.  
     
     
         4 . A method of treating a disease of the central nervous system in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a histone deacetylase inhibitor compound.  
     
     
         5 . The method of  claim 4 , wherein the disease is a polyglutamine expansion disease.  
     
     
         6 . The method of  claim 5 , wherein the polyglutamine expansion disease is Huntington's disease.  
     
     
         7 . The method of  claim 4 , wherein the individual is a human.  
     
     
         8 . The method of  claim 4 , wherein the inhibitor of histone deacetylase is selected from:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.  
     
     
         9 . The method of  claim 8 , wherein the histone deacetylase inhibitor compound is selected from:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.  
     
     
         10 . A method of treating a brain cancer in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a histone deacetylase inhibitor compound.  
     
     
         11 . The method of  claim 10 , wherein the histone deacetylase inhibitor is selected from:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.  
     
     
         12 . The method of  claim 11 , wherein the histone deacetylase inhibitor is selected from:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.